



Universiteit  
Leiden  
The Netherlands

## **Emerging risk factors for venous thromboembolism: The role of commonly prescribed drugs for cardiovascular disease and inflammatory disorders**

Orsi Loureiro de Andrade, F.

### **Citation**

Orsi Loureiro de Andrade, F. (2020, June 30). *Emerging risk factors for venous thromboembolism: The role of commonly prescribed drugs for cardiovascular disease and inflammatory disorders*. Retrieved from <https://hdl.handle.net/1887/123183>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/123183>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/123183> holds various files of this Leiden University dissertation.

**Author:** Orsi, Loureiro de Andrade F.

**Title:** Emerging risk factors for venous thromboembolism: The role of commonly prescribed drugs for cardiovascular disease and inflammatory disorders

**Issue Date:** 2020-06-30

## **Summary and Discussion**

## **SUMMARY AND GENERAL DISCUSSION**

The aim of this thesis was to investigate the association of commonly prescribed drugs, such as statins and glucocorticoids, with changes in hemostasis and VTE risk. In this chapter we provide an overview of our main findings. Furthermore, we consider the clinical implications and discuss directions for future research.

### **STATINS TO MODULATE HYPERCOAGULABILITY AND THROMBOTIC RISK**

In **Chapter 2**, we performed a narrative review on the effect of statins on hemostasis and VTE risk. We observed that previous data have suggested that statins might decrease VTE risk. The JUPITER trial, which is thus far the only statin trial performed with VTE as the outcome of interest, showed that rosuvastatin may reduce the risk of VTE in 40% in apparently healthy men over the age of 50 years and women over 60 years old [1]. The authors called “apparently healthy persons” those individuals with no history of cardiovascular disease, low levels of low-density lipoprotein (LDL) cholesterol and increased levels of high-sensitivity C-reactive protein level [1]. We also described that meta-analyses of observational studies reported a VTE risk reduction of 14 - 54% and meta-analyses of randomized controlled trials (RCT) reported a 11 – 25% reduction in VTE risk among statin users [2-4]. Furthermore, a meta-analysis of observational studies showed that statins may reduce the overall risk of recurrent VTE by 27% [5].

Although these findings might encourage the use of statins for VTE prevention, the results must be interpreted with caution for several reasons. First, data from the JUPITER trial may be questioned because the results on VTE came from a secondary analysis of the original trial, in which the primary outcome was the occurrence of a first major cardiovascular event (myocardial infarction or unstable angina, stroke, arterial revascularization procedure, or confirmed death from cardiovascular causes); moreover, the results may have run into statistical problem of small numbers, since in the statin treatment arm only 34 participants developed a venous thrombotic event, and chance, or a type I error, may therefore have influenced this result. Second, meta-analysis of observational studies has limitations, related to the studies included, that cannot be fully addressed, such as confounding and particularly survivor bias [6, 7]. As examples of potential bias in observational studies, the underlying disease severity in patients selected

for statin therapy may be different, even milder than that in patients for whom statin was not indicated (healthy user effect) [8], the inclusion of prevalent statin users results in missing the events that occurred in statin users before the inclusion, early after starting treatment (survivor bias), and in addition, observational studies are not able to control for those patients who do or do not adhere to statin treatment (adherence bias) [6]. Third, meta-analyses of RCTs included non-published data, which could have led to biased estimates, and were influenced by the results of the JUPITER trial. Fourth, the meta-analysis that pointed to a potential role of statin therapy in secondary VTE prophylaxis relied on a small number of observational studies, and a biased association between statin use and prevention of VTE recurrence cannot be ruled out. So far, the use of statins for secondary VTE prophylaxis has not been evaluated in well-designed intervention studies, such as RCTs.

More high quality evidence is needed to establish whether statin therapy is effective to prevent incident or recurrent VTE. However, the only trial currently being conducted for evaluating the effect of statins use on venous events, the SAVER trial (NCT02679664), aims to determine the feasibility of recruitment of VTE patients and to assess whether rosuvastatin can reduce post-thrombotic syndrome in VTE patients. The risk of recurrent VTE may be evaluate as a secondary endpoint if the recruitment is feasible. Therefore, the question on the role of statin therapy in VTE prevention will probably remain unanswered for the following years.

A possible explanation for the lack of conducting such costly studies is the fact that a clear biological mechanism behind the supposed effect of statins on the pathophysiology of VTE is not known. For this reason, the biological effect of statins on hemostasis was reviewed in **Chapter 2**, in which we observed that basic research and clinical studies suggest that statins are capable of decreasing platelet activity [9-21], downregulate both initiation and amplification phases of coagulation [12, 14, 22-32] and stimulate fibrinolysis [33-37]. However, the mechanisms underlying the statins effect on several phases of hemostasis are not explained. Thus, the reported findings raise suspicions of a problem similar to that encountered in the parable of “the blind men and the elephant”, in which blind men reported different opinions about what was an elephant after touching only one part of the animal. This means that the inability of observing a problem as a whole may lead to opposing opinions on the same issue. As a result of such

imprecise findings, the potential antithrombotic property of statins is regarded with skepticism.

The best known mechanism by which statins may impair hemostasis is the direct downregulation of TF expression on endothelium cells and monocytes [38-42]. Several studies consistently demonstrated that statins affect hemostasis particularly by downregulating TF expression on endothelium cells and monocytes through a direct inhibitory effect on transcriptional activation of TF gene [38-42]. Although this mechanism can explain, in part, the downregulation of coagulation pathways, it cannot explain the impairment in platelet function and fibrinolysis. Furthermore, TF is not associated with the risk of VTE [43] and, therefore, a decrease in TF antigen or activity could not explain the supposed effect of statins on VTE prophylaxis. In this regard, the use of standard methods to measure the individual hemostatic potential, such as global assays of coagulation or established biomarkers of VTE risk, could be helpful to provide more accurate data on the capacity of statins to revert a hypercoagulability state or even cause hypocoagulability.

Therefore, in **Chapter 3** we investigated whether rosuvastatin use decreases thrombin generation potential in patients with a prior VTE in the STATins Reduce Thrombophilia (START) trial. Thrombin generation potential is a global coagulation test that reproduces the kinetics of thrombin formation [44, 45], reflects the coagulation potential of an individual [46-48] and also predicts the risk of a first and recurrent VTE [49-51]. The START trial is a RCT aimed to investigate if statin improves the coagulation profile in patients with prior VTE. After anticoagulation withdrawal, patients with VTE were randomized to rosuvastatin 20mg/day for 4 weeks or no intervention. The thrombin generation potential was assessed at baseline and at end of study by means of the thrombin generation assay (TGA), which is a global coagulation test using the Calibrated Automated Thrombogram® (Diagnostica Stago, France).

The primary endpoint was the difference in change in endogenous thrombin potential (ETP) and peak between rosuvastatin users and non-users. Analyses were done by intention to treat and regression models were adjusted for age and sex. The study comprised 245 patients, 126 rosuvastatin users and 119 non-users. Mean age was 58 years, 61% were men, 49% had unprovoked VTE and 75% had cardiovascular (CV) risk factors. Endogenous thrombin potential (ETP) increased from baseline to end of study in non-statin users (mean change: 97.22nM\*min; 95%CI 40.92 to 153.53) and decreased in

rosuvastatin users (mean change:  $-24.94\text{nM}\cdot\text{min}$ ; 95%CI  $-71.81$  to  $21.93$ ). The mean difference in ETP change between treatments was  $-120.24\text{nM}\cdot\text{min}$  (95%CI  $-192.97$  to  $-47.51$ ), yielding a 10.4% ETP reduction by rosuvastatin. Thrombin peak increased in both non-statin (mean change:  $20.69\text{nM}$ ; 95%CI  $9.80$  to  $31.58$ ) and rosuvastatin users (mean change:  $8.41\text{nM}$ ; 95%CI  $-0.86$  to  $17.69$ ). The mean difference in peak change between treatments was  $-11.88\text{nM}$  (95%CI  $-26.11$  to  $2.35$ ), yielding a 5% peak reduction by rosuvastatin. Other thrombin generation parameters, such as time to peak, lag time and velocity index, did not change substantially. All these results were not materially affected when we restricted the analyses to patients who did not develop an acute infection during follow-up, and when we adjusted our findings for age and sex. Predefined subgroup analyses with regard to sex and VTE cause (provoked or unprovoked) revealed similar results as in the main analysis, while the reduction in ETP by rosuvastatin appeared more pronounced in participants with CV risk factors and with pulmonary embolism than in those without CV risk factors and with deep vein thrombosis, respectively.

We concluded that rosuvastatin 20mg/day improves the coagulation profile in patients who had a VTE by reducing thrombin generation potential after anticoagulation withdrawal. Given that thrombin generation potential is associated with a first VTE [16, 28, 29, 31] and can predict the risk of recurrent VTE [25-27, 30], our finding could be interpreted as statins having the potential to decrease the risk of recurrence. Although our results do not answer the question whether this effect of rosuvastatin on changing the coagulation profile has clinical significance in terms of reducing VTE risk, they provide a basis for interventional studies necessary to establish the efficacy of rosuvastatin on VTE prophylaxis.

Another open question is whether the effect of statins on hemostasis is dependent of the drug-related lipid-lowering effect. Studies *in vitro* have shown that statins are capable of inhibiting TF expression and platelet activity by different mechanisms from that involved in the lipid-lowering process [11, 20, 52]. From a clinical perspective, it is not possible, however, to rule out that the effect of statin use on hemostasis is due to a decrease in the serum levels of lipids, since many lipoproteins have been related to coagulation activity [16, 53, 54]. Recently, apolipoproteins (apos) A and B, which are the major functional components of high and low density lipoprotein respectively, have been associated with altered coagulation profile [53]. In **Chapter 4**, we further evaluated the association of apos C-I,-II,-III and E with hemostasis and with VTE risk. Apos C-I, C-II,

C-III and E have been associated with risk of arterial thrombotic diseases and whether these apos have prothrombotic properties and are also associated with risk of VTE is not known. The study population comprised a total of 127 VTE patients and 299 controls randomly selected from the Multiple Environmental and Genetic Assessment of Risk Factors for Venous Thrombosis study (1999–2004), in the Netherlands. The apos were quantified using mass spectrometry (LC/MS/MS) and their levels were analysed as continuous variable (per SD increase). In controls, increases in levels of apolipoproteins were associated with increases in levels of vitamin K dependent factors, factor XI, antithrombin and clot lysis time. Additionally, increasing apos C-III and E levels were associated with higher factor VIII and von Willebrand factor levels. Levels of C-reactive protein were not associated with any apolipoprotein. The age and sex adjusted odds ratios of apos E, C-III, CII and CI to the risk of venous thrombosis were 1.21 (95% CI, 0.98-1.49), 1.19 (0.99-1.44), 1.24 (0.95-1.61) and 1.06 (95% CI, 0.87-1.30) per SD increase, respectively. These odds ratios did not attenuate after adjustments for statin use, estrogen use, BMI, alcohol use, and self-reported diabetes. We concluded that apos C-I, C-II, C-III and E are associated with several coagulation factors. However, whether these apos are also associated with an increased risk of VTE remains to be established as numbers on VTE outcomes were small in our study. These findings are, however, in line with previous population studies that showed that apo A and B are associated with a mild increase in the risk of VTE (roughly 30-50%) despite being consistently associated with levels of coagulation markers [53]. Furthermore, only apos C-III and E were associated with levels of FVIII and VWF, which coagulation proteins are well known risk factors for VTE [55-57]. A potential direct effect of statins on coagulation factors release by the liver or by the endothelium may play a role in the association of statins use and hemostasis. Future clinical studies to investigate/ confirm the effects of statins and apos to modulate hypercoagulability and thrombotic risk are warranted.

## **ROLE OF GLUCOCORTICOIDS IN THROMBOTIC RISK: PLAYERS OR VIEWERS?**

Systemic glucocorticoids are steroid hormones prescribed to decrease inflammation in diseases and conditions such as arthritis (rheumatoid arthritis), systemic lupus erythematosus, inflammatory bowel diseases, asthma, bronchitis, allergy and neoplasia [58-62]. These drugs are potent anti-inflammatory drugs widely used in patients with



different diseases of various severity, from autoimmune to neoplastic disorders and pulmonary diseases that, in contrast, can cause severe adverse events. Experimental studies show that glucocorticoids increase coagulation factor levels and possibly the risk of VTE. Although the risk of VTE has been reported to be two- to three-fold increased with the use of glucocorticoids [63-65], several confounders may account for the reported association, such as chronic diseases [58-62], periods of disease exacerbation or flares [59, 66, 67], comorbidities [68] and toxicity of concomitant medications [69]. The effect of the underlying disease on the risk of VTE is of particular concern. Firstly, because asthma, rheumatoid arthritis, inflammatory bowel diseases, lupus erythematosus, Sjögren syndrom, polymyositis, multiple sclerosis, immune thrombocytopenia and malignancy, which are widely treated with oral glucocorticoids, have been associated with a 3 to 9-fold increased risk of VTE [59-62, 66, 67, 70, 71]. Second, because the suppression of the underlying inflammatory process by glucocorticoid use might otherwise contribute to prevent thrombotic events [68]. The latter is in line with the observations that glucocorticoid use are associated with decreased VWF and platelet activities and increased natural anticoagulants in the context of inflammatory states [72, 73]. Such effects of glucocorticoids on coagulation markers are consistent with a downregulation in hemostasis.

Therefore, in **Chapter 5** we evaluated the risk of first and recurrent VTE associated with the use of oral glucocorticoids, addressing the issue of potential confounders by employing the self-controlled case-series (SCCS) method. The periods of exposure to oral glucocorticoids were divided into: 1) the seven day-period immediately before a prescription was given, 2) the first 7 days with glucocorticoid treatment, 3) 8-30 days with oral glucocorticoid treatment, 4) 31-180 days with oral glucocorticoid treatment and 5) >180 days with oral glucocorticoid treatment. In addition, we evaluated the effect of oral glucocorticoids on the risk of recurrent VTE in a cohort design. Patients with VTE from the MEGA study were linked to the Dutch Foundation for Pharmaceutical Statistics (SFK) register based on a combination of age, sex, digit postal code and vitamin K antagonist use within the first month after the initial VTE. Prescriptions of oral glucocorticoids in the period of the MEGA study were identified. The risk for the first VTE was estimated using SCCS method and comparing the within-patients rate of events during periods of exposure and periods of non-exposure to oral glucocorticoids. The association between oral glucocorticoids and recurrent VTE was examined using Cox regression models and two different approaches: 1) comparing the recurrence rates of

VTE in patients whose first event was associated, or not, with an oral glucocorticoid treatment and 2) comparing the recurrence rates of VTE in patients with and without current use of oral glucocorticoids.

A total of 2547 patients were linked to the SFK data register, from those 363 received at least one outpatient prescription of oral glucocorticoids. The risk for a first VTE event was 3.5-fold higher in the aggregated period of oral glucocorticoid treatment as compared with baseline periods (incident rate ratio [IRR] 3.5, 95% confidence interval [CI] 2.6-4.8). IRR of a first VTE event was 2.5 (95% CI, 1.1– 5.7) in the week before treatment started, 5.3 (95% CI, 2.9 – 9.5) during the first 7 days with treatment, 3.7 (95% CI, 2.6 – 5.2) until six months with treatment and 1.6 (95% CI, 0.8 – 3.1) after 6 months with oral glucocorticoids, as compared with baseline period. A dose-dependent relationship between oral glucocorticoid treatment and VTE risk was observed as the IRR increased from 3.4 (95% CI, 2.3 – 5.0) with 30-day cumulative doses below 300mg to 4.9 (95% CI, 1.7 – 14.0) with 30-day cumulative doses above 2000mg, as compared with baseline periods. IRRs for DVT (3.9; 95% CI, 2.9 – 9.5) and PE (3.1; 95% CI, 2.0 – 4.9) were similar and IRR for unprovoked VTE (2.4; 95% CI, 1.3 – 4.7) was lower than the IRR for provoked VTE (4.2; 95% CI, 2.9 – 6.0). The rates of recurrent VTE were elevated in patients with unprovoked VTE and in those who had their first VTE during a period of oral glucocorticoid treatment, either if the first event was otherwise classified as provoked or unprovoked. The adjusted HRs for recurrent VTE were 1.6 (95% CI, 1.2 – 2.0) in patients with unprovoked first VTE not using oral glucocorticoids at the time of their first event, 2.1 (95% CI, 1.2 – 3.8) in those who had a provoked first VTE while using oral glucocorticoids and 2.3 (95% CI, 1.2 – 7.0) in those with an unprovoked first VTE while using the drug, as compared with patients with a provoked first event not using oral glucocorticoids at the time of their first event. The risk for recurrent VTE was 2.7-fold increased (95% CI, 1.6 – 4.8) during treatment periods as compared to baseline periods and did not vary substantially according to the length of the treatment (below or above 180 days). We concluded that patients receiving oral glucocorticoids had a more than three-fold increase in the risk for first VTE event. The observed risk for VTE was associated with the underlying disease (pre-exposure period) but increased further after oral glucocorticoids were prescribed. The risk for a VTE recurrence was 2-fold increased during a period of oral glucocorticoid treatment. Additionally, patients using oral glucocorticoids at the time of their first VTE event had higher risk for subsequent events than those without glucocorticoids at that time. The results underscore that treatment

strategies to prevent VTE in patients treated with oral glucocorticoids are needed. As oral glucocorticoids are commonly prescribed for a wide range of conditions, awareness of the drug associated risk for VTE may improve treatment strategies to prevent this complication. Although there is not enough evidence to support changes in current indication for oral glucocorticoid treatment, patients with higher risk for VTE, including those with a prior VTE event, should be treated and followed with caution. Given the risk for incident and recurrent VTE associated with oral glucocorticoids, future clinical trials are warranted to examine whether prophylactic anticoagulation is beneficial for patients starting oral glucocorticoid treatment, in particular for those at higher risk for VTE. As an example, the incidence rate of VTE in patients with active inflammatory bowel disease during non-hospitalized periods is 9 per 1000 person-years (59). Assuming that the relative risk of VTE increases 3-fold when a glucocorticoid treatment is started and anticoagulation decreases the risk of VTE by 80% (74), a trial with 470 participants receiving anticoagulation and 470 receiving placebo would be statistically powered (2 sided  $\alpha=5\%$ , power=80%) to determine whether anticoagulants reduce the risk of VTE in these patients.

## Conclusions

Statins and systemic glucocorticoids are commonly prescribed drugs that interfere with the risk of VTE in different ways. Systemic glucocorticoid use increases the relative risk of first VTE by more than three-fold and *confers* an additional 5% *absolute risk* of recurrent VTE per year. These data underscore that prior use of systemic glucocorticoids should be considered when identifying provoking factors of VTE and that treatment strategies to prevent glucocorticoid-associated VTE are needed, especially in patients with higher risk for VTE. Since there is no evidence on which is the best treatment strategy to prevent glucocorticoid-associated VTE, and given the high risk of incident and recurrent VTE associated with oral glucocorticoids, clinical trials are warranted to examine whether prophylactic anticoagulation is beneficial for patients starting an oral glucocorticoid treatment.

On the other hand, rosuvastatin use may reduce the risk of first VTE by 40%. Although the mechanisms behind this association are not fully elucidated, this thesis has shown that rosuvastatin is capable of decreasing the thrombin generation potential by 10% in patients with a prior VTE. The finding that rosuvastatin modulates the coagulation

profile supports the hypothesis that rosuvastatin may be capable of reducing the risk of recurrent VTE, while not increasing the risk of bleeding. However, clinical evidence on the effect of statins on recurrent VTE risk is lacking and the role of statin use in recurrent VTE prophylaxis needs careful evaluation/confirmation in well-defined trials.

In conclusion, this thesis has shown that both statins and systemic glucocorticoids are capable of affecting the risk of VTE, improving the knowledge on the influence of this two commonly prescribed drugs on VTE pathophysiology. These findings have the potential to further refine the assessment of VTE risk since they highlight that the use of these drugs should be considered when evaluating the risk of VTE. Finally, this thesis provides insight into new therapeutic approaches since the results underscore that treatment strategies on VTE prevention in patients already taken statins, which may be sufficient for VTE prevention, are lacking. Treatment strategies to prevent glucocorticoid-associated VTE are also needed.

## Reference List

1. Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Ridker PM. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. *The New England journal of medicine*. 2009; **360**: 1851-61. 10.1056/NEJMoa0900241.
2. Kunutsor SK, Seidu S, Khunti K. Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis. *The Lancet Haematology*. 2017; **4**: e83-e93. 10.1016/S2352-3026(16)30184-3.
3. Pai M, Evans NS, Shah SJ, Green D, Cook D, Crowther MA. Statins in the prevention of venous thromboembolism: a meta-analysis of observational studies. *Thromb Res*. 2011; **128**: 422-30. 10.1016/j.thromres.2011.05.012.
4. Rahimi K, Bhala N, Kamphuisen P, Emberson J, Biere-Rafi S, Krane V, Robertson M, Wikstrand J, McMurray J. Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. *PLoS Med*. 2012; **9**: e1001310. 10.1371/journal.pmed.1001310.
5. Kunutsor SK, Seidu S, Khunti K. Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies. *European heart journal*. 2017; **38**: 1608-12. 10.1093/eurheartj/ehx107.
6. van Rein N, Cannegieter SC, le Cessie S, Rosendaal FR, Reitsma PH, van der Meer FJ, Lijfering WM. Statins and Risk of Bleeding: An Analysis to Evaluate Possible Bias Due to Prevalent Users and Healthy User Aspects. *Am J Epidemiol*. 2016; **183**: 930-6. 10.1093/aje/kwv255.
7. Danaei G, Tavakkoli M, Hernan MA. Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. *Am J Epidemiol*. 2012; **175**: 250-62. 10.1093/aje/kwr301.
8. Thomsen RW. The lesser known effects of statins: benefits on infectious outcomes may be explained by "healthy user" effect. *BMJ*. 2006; **333**: 980-1. 10.1136/bmj.39024.513218.BE.

9. Ali FY, Armstrong PC, Dhanji AR, Tucker AT, Paul-Clark MJ, Mitchell JA, Warner TD. Antiplatelet actions of statins and fibrates are mediated by PPARs. *Arterioscler Thromb Vasc Biol.* 2009; **29**: 706-11. 10.1161/ATVBAHA.108.183160.
10. Puccetti L, Pasqui AL, Pastorelli M, Bova G, Cercignani M, Palazzuoli A, Angori P, Auteri A, Bruni F. Time-dependent effect of statins on platelet function in hypercholesterolaemia. *European journal of clinical investigation.* 2002; **32**: 901-8.
11. Haramaki N, Ikeda H, Takenaka K, Katoh A, Sugano R, Yamagishi S, Matsuoka H, Imaizumi T. Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: possible improvement of intraplatelet redox imbalance via HMG-CoA reductase. *Arterioscler Thromb Vasc Biol.* 2007; **27**: 1471-7. 10.1161/ATVBAHA.106.128793.
12. Ural AU, Yilmaz MI, Avcu F, Yalcin A. Treatment with cerivastatin in primary mixed hyperlipidemia induces changes in platelet aggregation and coagulation system components. *International journal of hematology.* 2002; **76**: 279-83.
13. Puccetti L, Pasqui AL, Pastorelli M, Bova G, Di Renzo M, Leo A, Cercignani M, Palazzuoli A, Auteri A, Bruni F. Platelet hyperactivity after statin treatment discontinuation. *Thromb Haemost.* 2003; **90**: 476-82. 10.1160/TH03-02-0111.
14. Dujovne CA, Harris WS, Altman R, Overhiser RW, Black DM. Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients. *The American journal of cardiology.* 2000; **85**: 350-3.
15. Aoki I, Aoki N, Kawano K, Shimoyama K, Maki A, Homori M, Yanagisawa A, Yamamoto M, Kawai Y, Ishikawa K. Platelet-dependent thrombin generation in patients with hyperlipidemia. *Journal of the American College of Cardiology.* 1997; **30**: 91-6.
16. Lippi G, Franchini M, Targher G. Arterial thrombus formation in cardiovascular disease. *Nature reviews Cardiology.* 2011; **8**: 502-12. 10.1038/nrcardio.2011.91.
17. Hamada M, Sugimoto M, Matsui H, Mizuno T, Shida Y, Doi M, Fukushima H, Nishio K, Yoshioka A, Shima M. Antithrombotic properties of pravastatin reducing intra-thrombus fibrin deposition under high shear blood flow conditions. *Thromb Haemost.* 2011; **105**: 313-20. 10.1160/TH10-09-0587.

18. Gertz K, Laufs U, Lindauer U, Nickenig G, Bohm M, Dirnagl U, Endres M. Withdrawal of statin treatment abrogates stroke protection in mice. *Stroke*. 2003; **34**: 551-7.
19. Ni R, Peleg T, Gross PL. Atorvastatin delays murine platelet activation in vivo even in the absence of endothelial NO synthase. *Arterioscler Thromb Vasc Biol*. 2012; **32**: 2609-15. 10.1161/ATVBAHA.112.300090.
20. Laufs U, Gertz K, Huang P, Nickenig G, Bohm M, Dirnagl U, Endres M. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. *Stroke*. 2000; **31**: 2442-9.
21. Schafer A, Fraccarollo D, Eigenthaler M, Tas P, Firmschild A, Frantz S, Ertl G, Bauersachs J. Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability. *Arterioscler Thromb Vasc Biol*. 2005; **25**: 1071-7. 10.1161/01.ATV.0000161926.43967.df.
22. Sahebkar A, Serban C, Mikhailidis DP, Undas A, Lip GY, Muntner P, Bittner V, Ray KK, Watts GF, Hovingh GK, Rysz J, Kastelein JJ, Banach M, Lipid, Blood Pressure Meta-analysis Collaboration G. Association between statin use and plasma D-dimer levels. A systematic review and meta-analysis of randomised controlled trials. *Thrombosis and haemostasis*. 2015; **114**: 546-57. 10.1160/TH14-11-0937.
23. Sahebkar A, Serban C, Ursoniu S, Mikhailidis DP, Undas A, Lip GY, Bittner V, Ray K, Watts GF, Hovingh GK, Rysz J, Kastelein JJ, Banach M, Lipid, Blood Pressure Meta-analysis Collaboration G. The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials. *Thrombosis and haemostasis*. 2016; **115**: 520-32. 10.1160/TH15-08-0620.
24. Ordulu E, Erdogan O. Early effects of low versus high dose atorvastatin treatment on coagulation and inflammation parameters in patients with acute coronary syndromes. *International journal of cardiology*. 2008; **128**: 282-4. 10.1016/j.ijcard.2007.06.030.
25. Tousoulis D, Bosinakou E, Kotsopoulou M, Antoniadis C, Katsi V, Stefanadis C. Effects of early administration of atorvastatin treatment on thrombotic process in

normocholesterolemic patients with unstable angina. *International journal of cardiology*. 2006; **106**: 333-7. 10.1016/j.ijcard.2005.02.011.

26. Undas A, Celinska-Lowenhoff M, Brummel-Ziedins KE, Brozek J, Szczeklik A, Mann KG. Simvastatin given for 3 days can inhibit thrombin generation and activation of factor V and enhance factor Va inactivation in hypercholesterolemic patients. *Arterioscler Thromb Vasc Biol*. 2005; **25**: 1524-5. 10.1161/01.ATV.0000168913.25278.38.

27. Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. *Circulation*. 2001; **103**: 2248-53.

28. Krysiak R, Okopien B. Effect of simvastatin on hemostasis in patients with isolated hypertriglyceridemia. *Pharmacology*. 2013; **92**: 187-90. 10.1159/000341909.

29. Morishita E, Asakura H, Saito M, Yamazaki M, Ontachi Y, Mizutani T, Kato M, Matsuda T, Nakao S. Elevated plasma levels of free-form of TFPI antigen in hypercholesterolemic patients. *Atherosclerosis*. 2001; **154**: 203-12.

30. Porreca E, Di Febbo C, Amore C, Di Castelnuovo A, Baccante G, Donati MB, Cuccurullo F, Iacoviello L. Effect of lipid-lowering treatment on factor VII profile in hyperlipidemic patients. *Thromb Haemost*. 2000; **84**: 789-93.

31. Morishita E, Minami S, Ishino C, Kanno M, Uotani C, Asakura H, Matsuda T, Nakao S. Atorvastatin reduces plasma levels of factor VII activity and factor VII antigen in patients with hyperlipidemia. *Journal of atherosclerosis and thrombosis*. 2002; **9**: 72-7.

32. Biedermann JS, Kruip M, van der Meer FJ, Rosendaal FR, Leebeek FWG, Cannegieter SC, Lijfering WM. Rosuvastatin use improves measures of coagulation in patients with venous thrombosis. *European heart journal*. 2018; **39**: 1740-7. 10.1093/eurheartj/ehy014.

33. Sahebkar A, Catena C, Ray KK, Vallejo-Vaz AJ, Reiner Z, Sechi LA, Colussi G. Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1. A



systematic review and meta-analysis of randomised controlled trials. *Thrombosis and haemostasis*. 2016; **116**: 162-71. 10.1160/TH15-10-0770.

34. Bruni F, Pasqui AL, Pastorelli M, Bova G, Di Renzo M, Cercigani M, Leo A, Auteri A, Puccetti L. Effect of atorvastatin on different fibrinolysis mechanisms in hypercholesterolemic subjects. *International journal of cardiology*. 2004; **95**: 269-74. 10.1016/j.ijcard.2003.08.003.

35. Dangas G, Smith DA, Unger AH, Shao JH, Meraj P, Fier C, Cohen AM, Fallon JT, Badimon JJ, Ambrose JA. Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect. *Thromb Haemost*. 2000; **83**: 688-92.

36. Dangas G, Badimon JJ, Smith DA, Unger AH, Levine D, Shao JH, Meraj P, Fier C, Fallon JT, Ambrose JA. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. *J Am Coll Cardiol*. 1999; **33**: 1294-304.

37. Bevilacqua M, Bettica P, Milani M, Vago T, Rogolino A, Righini V, Santoli E, Norbiato G. Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease. *The American journal of cardiology*. 1997; **79**: 84-7.

38. Ferro D, Basili S, Alessandri C, Cara D, Violi F. Inhibition of tissue-factor-mediated thrombin generation by simvastatin. *Atherosclerosis*. 2000; **149**: 111-6.

39. Camera M, Toschi V, Comparato C, Baetta R, Rossi F, Fuortes M, Ezekowitz MD, Paoletti R, Tremoli E. Cholesterol-induced thrombogenicity of the vessel wall: inhibitory effect of fluvastatin. *Thromb Haemost*. 2002; **87**: 748-55.

40. Nagata K, Ishibashi T, Sakamoto T, Ohkawara H, Shindo J, Yokoyama K, Sugimoto K, Sakurada S, Takuwa Y, Nakamura S, Teramoto T, Maruyama Y. Rho/Rho-kinase is involved in the synthesis of tissue factor in human monocytes. *Atherosclerosis*. 2002; **163**: 39-47.

41. Eto M, Kozai T, Cosentino F, Joch H, Luscher TF. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. *Circulation*. 2002; **105**: 1756-9.

42. Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. *Arterioscler Thromb Vasc Biol.* 1997; **17**: 265-72.
43. Manly DA, Boles J, Mackman N. Role of tissue factor in venous thrombosis. *Annual review of physiology.* 2011; **73**: 515-25. 10.1146/annurev-physiol-042210-121137.
44. Brummel-Ziedins K, Vossen CY, Rosendaal FR, Umezaki K, Mann KG. The plasma hemostatic proteome: thrombin generation in healthy individuals. *J Thromb Haemost.* 2005; **3**: 1472-81. 10.1111/j.1538-7836.2005.01249.x.
45. Morishima Y, Kamisato C. Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay. *Am J Clin Pathol.* 2015; **143**: 241-7. 10.1309/AJCPQ2NJD3PXFTUG.
46. Dielis AW, Castoldi E, Spronk HM, van Oerle R, Hamulyak K, Ten Cate H, Rosing J. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. *J Thromb Haemost.* 2008; **6**: 125-31. 10.1111/j.1538-7836.2007.02824.x.
47. Segers O, van Oerle R, ten Cate H, Rosing J, Castoldi E. Thrombin generation as an intermediate phenotype for venous thrombosis. *Thromb Haemost.* 2010; **103**: 114-22. 10.1160/TH09-06-0356.
48. ten Cate-Hoek AJ, Dielis AW, Spronk HM, van Oerle R, Hamulyak K, Prins MH, ten Cate H. Thrombin generation in patients after acute deep-vein thrombosis. *Thromb Haemost.* 2008; **100**: 240-5.
49. Ten Cate H. Thrombin generation in clinical conditions. *Thromb Res.* 2012; **129**: 367-70. 10.1016/j.thromres.2011.10.017.
50. Tripodi A. Thrombin Generation Assay and Its Application in the Clinical Laboratory. *Clin Chem.* 2016; **62**: 699-707. 10.1373/clinchem.2015.248625.

51. van Veen JJ, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet? *Br J Haematol.* 2008; **142**: 889-903. 10.1111/j.1365-2141.2008.07267.x.
52. Vaughan CJ, Gotto AM, Jr., Basson CT. The evolving role of statins in the management of atherosclerosis. *Journal of the American College of Cardiology.* 2000; **35**: 1-10.
53. Morelli VM, Lijfering WM, Bos MHA, Rosendaal FR, Cannegieter SC. Lipid levels and risk of venous thrombosis: results from the MEGA-study. *Eur J Epidemiol.* 2017. 10.1007/s10654-017-0251-1.
54. Moyer MP, Tracy RP, Tracy PB, van't Veer C, Sparks CE, Mann KG. Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. *Arterioscler Thromb Vasc Biol.* 1998; **18**: 458-65.
55. Kraaijenhagen RA, in't Anker PS, Koopman MM, Reitsma PH, Prins MH, van den Ende A, Buller HR. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. *Thromb Haemost.* 2000; **83**: 5-9.
56. Kyle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, Weltermann A, Speiser W, Lechner K, Eichinger S. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. *N Engl J Med.* 2000; **343**: 457-62. 10.1056/NEJM200008173430702.
57. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. *Lancet.* 1995; **345**: 152-5.
58. Bertoletti L, Quenet S, Mismetti P, Hernandez L, Martin-Villasclaras JJ, Tolosa C, Valdes M, Barron M, Todoli JA, Monreal M, Investigators R. Clinical presentation and outcome of venous thromboembolism in COPD. *The European respiratory journal.* 2012; **39**: 862-8. 10.1183/09031936.00058811.
59. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. *Lancet.* 2010; **375**: 657-63. 10.1016/S0140-6736(09)61963-2.

60. Peeters PJ, Bazelier MT, Uitdehaag BM, Leufkens HG, De Bruin ML, de Vries F. The risk of venous thromboembolism in patients with multiple sclerosis: the Clinical Practice Research Datalink. *J Thromb Haemost.* 2014; **12**: 444-51. 10.1111/jth.12523.
61. Carruthers EC, Choi HK, Sayre EC, Avina-Zubieta JA. Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study. *Annals of the rheumatic diseases.* 2016; **75**: 110-6. 10.1136/annrheumdis-2014-205800.
62. Avina-Zubieta JA, Jansz M, Sayre EC, Choi HK. The Risk of Deep Venous Thrombosis and Pulmonary Embolism in Primary Sjogren Syndrome: A General Population-based Study. *The Journal of rheumatology.* 2017; **44**: 1184-9. 10.3899/jrheum.160185.
63. Huerta C, Johansson S, Wallander MA, Garcia Rodriguez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. *Archives of internal medicine.* 2007; **167**: 935-43. 10.1001/archinte.167.9.935.
64. Johannesdottir SA, Horvath-Puho E, Dekkers OM, Cannegieter SC, Jorgensen JO, Ehrenstein V, Vandenbroucke JP, Pedersen L, Sorensen HT. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. *JAMA Intern Med.* 2013; **173**: 743-52. 10.1001/jamainternmed.2013.122.
65. Waljee AK, Rogers MA, Lin P, Singal AG, Stein JD, Marks RM, Ayanian JZ, Nallamotheu BK. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. *BMJ.* 2017; **357**: j1415. 10.1136/bmj.j1415.
66. Majoor CJ, Kamphuisen PW, Zwinderman AH, Ten Brinke A, Amelink M, Rijssenbeek-Nouwens L, Sterk PJ, Buller HR, Bel EH. Risk of deep vein thrombosis and pulmonary embolism in asthma. *The European respiratory journal.* 2013; **42**: 655-61. 10.1183/09031936.00150312.
67. Higgins PD, Skup M, Mulani PM, Lin J, Chao J. Increased risk of venous thromboembolic events with corticosteroid vs biologic therapy for inflammatory bowel disease. *Clinical gastroenterology and hepatology : the official clinical practice journal*

*of the American Gastroenterological Association.* 2015; **13**: 316-21. 10.1016/j.cgh.2014.07.017.

68. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, McInnes IB, Haentzschel H, Gonzalez-Gay MA, Provan S, Semb A, Sidiropoulos P, Kitas G, Smulders YM, Soubrier M, Szekanecz Z, Sattar N, Nurmohamed MT. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. *Annals of the rheumatic diseases.* 2010; **69**: 325-31. 10.1136/ard.2009.113696.

69. van der Goes MC, Jacobs JW, Boers M, Andrews T, Blom-Bakkens MA, Buttgerit F, Caeyers N, Cutolo M, Da Silva JA, Guillevin L, Kirwan JR, Rovensky J, Severijns G, Webber S, Westhovens R, Bijlsma JW. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. *Annals of the rheumatic diseases.* 2010; **69**: 1913-9. 10.1136/ard.2009.124958.

70. Ruggeri M, Toso A, Palandri F, Polverelli N, Mazzucconi MG, Santoro C, Gaidano G, Lunghi M, Zaja F, De Stefano V, Sartori R, Fazi P, Rodeghiero F, Gruppo Italiano Malattie EdAA, Thrombocytopenias Working Party GSITP. Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors. *J Thromb Haemost.* 2014; **12**: 1266-73. 10.1111/jth.12636.

71. Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. *Blood.* 2013; **122**: 1712-23. 10.1182/blood-2013-04-460121.

72. van Zaane B, Nur E, Squizzato A, Gerdes VE, Buller HR, Dekkers OM, Brandjes DP. Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors. *Journal of thrombosis and haemostasis : JTH.* 2010; **8**: 2483-93. 10.1111/j.1538-7836.2010.04034.x.

73. Isidori AM, Minnetti M, Sbardella E, Graziadio C, Grossman AB. Mechanisms in endocrinology: The spectrum of haemostatic abnormalities in glucocorticoid excess and defect. *European journal of endocrinology.* 2015; **173**: R101-13. 10.1530/EJE-15-0308.

